Daniel A. Ollendorf on Muck Rack

Daniel A. Ollendorf

Boston
As seen in: Wiley Online Library, Los Angeles Times, The Minnesota Star Tribune, Newsday, STAT, Pittsburgh Tribune-Review, Health Affairs, Annals of Internal Medicine, American Journal of Managed Care, Walla Walla Union-Bulletin and
CSO @icer_review Value Measurement/Global Health @TuftsCEVR Author, The Right Price (bit.ly/3sTvHx9) Fan of sanity Tweets are my own, RT not endorsement
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Daniel A.

Contact Daniel A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Assessing the population-health loss from funding high-cost medicines: Case studies from Colombia and the Dominican Republic

|
By Natalia Jorgensen, Daniel A. Ollendorf, Pamela Gongora-Salazar, Catalina Argüello Gutiérrez, Lucía Bettati, Marcella Distrutti, Ursula Giedion, Santiago Palacio-Ciro
| Value in Health Journal Verified
1The World Bank, Washington D.C., USA 2Soul Healthecare Consulting, Buenos Aires, Argentina 3University of York, Centre for Health Economics, York, U.K 4Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Institute for Clinical and Economic Review (ICER), Boston, MA, USA 5San Andres University, Buenos Aires, Argentina 6Inter-American Development Bank Health, Nutrition and Population Division, Washington D.C., U.S.A 7Inter-American Development Bank, Health, Nutrition...
Open in Who Shared Issue with article?

Harmonizing HTA Evidence Needs and Expectations: Challenges and Opportunities to Improve Evidence Generation, Ensure Access and Affordability

|
By Sarah Emond, Wim Goettsch, Daniel A. Ollendorf
| Wiley Online Library Verified
CONFLICT OF INTEREST The authors declared no competing interests for this work. References 1, , , & Understanding the history and use of the accelerated approval pathway (Avalere, Washington, DC, USA) <https://avalere.com/insights/understanding-the-history-and-use-of-the-accelerated-approval-pathway> (2022). Accessed October 10, 2024. 2, , & Marketing authorisations for unmet medical needs: a critical appraisal of regulatory pathways in the European Union. Int. J. Pharm. 642, 123193 (2023). 3 et al.
Open in Who Shared Issue with article?

From “Price Controls” To Robust Public Conversation: How CMS Can Move Drug Price Negotiation Into The Light

|
By Daniel A. Ollendorf, Leah Z. Rand, Helen Mooney, Marie Phillips, Anirban Basu
| Health Affairs Verified
From the time that the Centers for Medicare and Medicaid Services (CMS) first provided public guidance on its intended approach for negotiating the price of the first 10 drugs selected for Medicare’s drug price negotiation program, there has been much speculation on the gaps in the available guidance. For example, it’s all well and good to say that a number of factors will be used in negotiation, but how are those factors weighted and used to determine a numeric output, the price?
Open in Who Shared Issue with article?
See all 25 licensed articles (29 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified